DFFN Diffusion Pharmaceuticals Inc.
Diffusion Pharmaceuticals, Inc. is a clinical stage company, which engages in the development of treatment for life threatening conditions. It offers Trans Sodium Crocetinate. The company was founded by David G. Kalergis and John L. Gainer in 2001 and is headquartered in Charlottesville, VA.
Company profile
Ticker
DFFN
Exchange
Website
CEO
Robert J. Cobuzzi
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
FERIS INTERNATIONAL, INC., RestorGenex Corp, Stratus Media Group, Inc, TITAN MOTORCYCLE CO OF AMERICA INC
SEC CIK
Corporate docs
IRS number
300645032
DFFN stock data
()
Investment data
Securities sold
Number of investors
Calendar
7 Aug 20
20 Oct 20
31 Dec 20
News
Financial summary
| Quarter (USD) | Jun 20 | Mar 20 | Sep 19 | Jun 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 19 | Dec 18 | Dec 17 | Dec 16 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Financial data from company earnings reports.
Recent insider trades
| Date | Owner | Security | Transaction | Code | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|
| 22 Sep 20 | William Robert Elder | Stock Option Common Stock | Grant | Aquire A | No | 0.82 | 70,000 | 57.4K | 70,000 |
| 8 Sep 20 | Cobuzzi Robert Joseph Jr. | Stock Option Common Stock | Grant | Aquire A | No | 0.79 | 475,000 | 375.25K | 475,000 |
| 1 Sep 20 | Jane H Hollingsworth | RSU Common Stock | Grant | Aquire A | No | 0 | 54,900 | 0 | 54,900 |
| 1 Sep 20 | Jane H Hollingsworth | Stock Option Common Stock | Grant | Aquire A | No | 0.91 | 67,400 | 61.33K | 67,400 |
Institutional ownership Q2 2020
8.2% owned by funds/institutions
13F holders |
Current |
|---|---|
| Total holders | 24 |
| Opened positions | 13 |
| Closed positions | 10 |
| Increased positions | 6 |
| Reduced positions | 1 |
13F shares |
Current |
|---|---|
| Total value | 5.14M |
| Total shares | 5.27M |
| Total puts | 0 |
| Total calls | 0 |
| Total put/call ratio | – |
Largest owners |
Shares | Value |
|---|---|---|
| Renaissance Technologies | 3.15M | $3.07M |
| BLK BlackRock | 830.47K | $810K |
| Geode Capital Management | 339.82K | $331K |
| Vanguard | 318.01K | $310K |
| Jane Street | 115.74K | $113K |
| NTRS Northern Trust | 107.89K | $105K |
| Squarepoint Ops | 79.88K | $78K |
| HRT Financial | 62.13K | $60K |
| SHANDA ASSET MANAGEMENT | 61K | $59K |
| VIRT Virtu Financial | 58.97K | $57K |
Financial report summary
?
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. junior Avg
|
|
New words:
aggregate, border, collect, deducting, dividend, ebb, Europe, European, flow, function, important, inducement, July, magnitude, NIID, placebo, powered, precautionary, ramp, reimpose, reinstate, reinstatement, relaxation, resurgence, Romanian, speed, statistical, stricter, unclear
Removed:
balance, beginning, initial, vested
Financial reports
10-Q
2020 Q2
Quarterly report
7 Aug 20
10-Q
2020 Q1
Quarterly report
11 May 20
10-K
2019 FY
Annual report
17 Mar 20
10-Q
2019 Q3
Quarterly report
8 Nov 19
10-Q
2019 Q2
Quarterly report
8 Aug 19
10-Q
2019 Q1
Quarterly report
9 May 19
10-K
2018 FY
Annual report
19 Mar 19
10-Q
2018 Q3
Quarterly report
13 Nov 18
10-Q
2018 Q2
Quarterly report
10 Aug 18
10-Q
2018 Q1
Quarterly report
10 May 18
Current reports
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
9 Oct 20
8-K
Diffusion Pharmaceuticals Strengthens Management Team with Appointmentof William Elder as General Counsel and Corporate Secretary
25 Sep 20
8-K
Regulation FD Disclosure
15 Sep 20
8-K
Other Events
10 Sep 20
8-K
Diffusion Pharmaceuticals Names Director Dr. Robert Cobuzzi as President and Chief Executive Officer
9 Sep 20
8-K
Diffusion Pharmaceuticals Appoints
4 Sep 20
8-K
Diffusion Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Business Update
10 Aug 20
8-K
Diffusion Pharmaceuticals Receives FDA Guidance for International Phase 1b/2b COVID-19 Clinical Program with TSC
29 Jul 20
8-K
Phase 1b dosing expected to begin this month
7 Jul 20
8-K
Submission of Matters to a Vote of Security Holders
17 Jun 20
Registration and prospectus
424B2
Prospectus for primary offering
2 Oct 20
S-3
Shelf registration
25 Sep 20
424B3
Prospectus supplement
8 Jun 20
S-1/A
IPO registration (amended)
3 Jun 20
S-1
IPO registration
29 May 20
D
$750K in options / securities to be acquired, sold $750K, 4 investors
27 May 20
424B5
Prospectus supplement for primary offering
19 May 20
D
$625K in options / securities to be acquired, sold $625K, 1 investor
15 May 20
S-8
Registration of securities for employees
13 May 20
424B3
Prospectus supplement
30 Dec 19
Proxies
DEFA14A
Additional proxy soliciting materials
29 Apr 20
DEF 14A
Definitive proxy
29 Apr 20
PRE 14A
Preliminary proxy
17 Apr 20
DEFA14A
Additional proxy soliciting materials
30 Apr 19
DEF 14A
Definitive proxy
30 Apr 19
DEFA14A
Additional proxy soliciting materials
30 Apr 18
DEF 14A
Definitive proxy
30 Apr 18
PRE 14A
Preliminary proxy
20 Apr 18
DEF 14A
Definitive proxy
18 Sep 17
PRE 14A
Preliminary proxy
8 Sep 17
Other
EFFECT
Notice of effectiveness
5 Oct 20
EFFECT
Notice of effectiveness
11 Jun 20
CORRESP
Correspondence with SEC
3 Jun 20
UPLOAD
Letter from SEC
2 Jun 20
EFFECT
Notice of effectiveness
30 Dec 19
CORRESP
Correspondence with SEC
23 Dec 19
UPLOAD
Letter from SEC
23 Dec 19
EFFECT
Notice of effectiveness
14 Nov 19
CORRESP
Correspondence with SEC
8 Nov 19
CORRESP
Correspondence with SEC
30 Oct 19
Ownership
4
Diffusion Pharmaceuticals / WILLIAM ROBERT ELDER ownership change
14 Oct 20
3
Diffusion Pharmaceuticals / WILLIAM ROBERT ELDER ownership change
14 Oct 20
4
Diffusion Pharmaceuticals / Jane H Hollingsworth ownership change
2 Oct 20
3
Diffusion Pharmaceuticals / Jane H Hollingsworth ownership change
2 Oct 20
4
Diffusion Pharmaceuticals / Robert Joseph Jr. Cobuzzi ownership change
11 Sep 20
4
Diffusion Pharmaceuticals / Robert W Adams ownership change
18 Jun 20
4
Diffusion Pharmaceuticals / Robert Joseph Jr. Cobuzzi ownership change
18 Jun 20
4
Diffusion Pharmaceuticals / Mark T Giles ownership change
18 Jun 20
4
Diffusion Pharmaceuticals / ALAN G LEVIN ownership change
18 Jun 20
SC 13G/A
Beneficial ownership report (amended)
14 Feb 20